Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.54USD
20 Apr 2018
Change (% chg)

$0.05 (+9.55%)
Prev Close
$0.49
Open
$0.50
Day's High
$0.54
Day's Low
$0.48
Volume
297,023
Avg. Vol
158,926
52-wk High
$2.42
52-wk Low
$0.29

Summary

Name Age Since Current Position

Paul Chaney

59 Chairman of the Board

Stephen From

54 2017 President, Director

Sarah Romano

2018 Chief Financial Officer, Corporate Controller

Lisa Brandano

2017 Vice President - Clinical Operations

Michael Manzo

57 Vice President - Engineering

Carol Assang

2017 Director - Clinical Operations

Mike Garanzini

2017 Chief Commercial Officer

Barbara Wirostko

51 2016 Chief Medical Officer

Thomas Balland

39 2012 Independent Director

Morton Goldberg

79 2008 Independent Director

Thomas Hancock

53 2007 Independent Director

Bernard Malfroy-Camine

64 2012 Independent Director

Praveen Tyle

2008 Independent Director

Biographies

Name Description

Paul Chaney

Mr. Paul G. Chaney is Chairman of the Board at Eyegate Pharmaceuticals, Inc. He is co-founder, President & CEO of PanOptica, Inc, a private venture-backed biopharmaceutical company that licenses and develops drugs for the treatment of important ophthalmic conditions, and has held such positions since March 2009. Prior to founding PanOptica, Mr. Chaney was Executive Vice President and President of Eyetech Pharmaceuticals Inc., or Eyetech. Prior to being acquired by OSI Pharmaceuticals Inc., Mr. Chaney served as Eyetech’s Chief Operating Officer, where he was responsible for the launch of Macugen, the first anti-VEGF treatment for neovascular age-related macular degeneration (wet-AMD), and was part of the executive team which led Eyetech’s initial public offering in 2004. Mr. Chaney has over 30 years of experience in the biopharmaceutical and ophthalmic medical device industry, including a variety of senior management positions at Pharmacia Corporation. He began his career as a sales representative for The Upjohn Company in 1980. Mr. Chaney has also served as a member of the board of directors of Eleven Biotherapeutics, Inc., a biologics company focusing on targeted protein therapeutics, since February 2014. Mr. Chaney earned a double BA in English and Biological Sciences from the University of Delaware.

Stephen From

Mr. Stephen From is President, Director of Eyegate Pharmaceuticals, Inc. Mr. From was formerly the Chief Financial Officer at Centelion SAS, an independent biotechnology subsidiary of Sanofi-Aventis. Prior to this, Mr. From spent several years as an investment banker specializing in the biotechnology and medical device sectors. He served as Director in the Global Healthcare Corporate and Investment Banking Group and Head of European Life Sciences for Bank of America Securities. Mr. From holds a BSc from the University of Western Ontario, an accounting diploma from Wilfred Laurier University and has qualified as a Chartered Accountant in Ontario, Canada. We believe Mr. From’s qualifications to sit on our board of directors include his executive leadership experience, financial expertise and the knowledge and understanding he has gained from serving as our President and Chief Executive Officer since 2005.

Sarah Romano

Ms. Sarah M. Romano is Chief Financial Officer, Corporate Controller of the Company. She joined the Company as Corporate Controller in 2016, and has been responsible for the Company’s accounting, tax, financial reporting, and internal controls. Prior to joining the Company, Ms. Romano served as Assistant Controller at TechTarget from June 2015 through August 2016 and Corporate Controller at Bowdoin Group, a healthcare-focused executive recruiting firm, from September 2013 through May 2015. Previously, she held financial reporting positions of increasing responsibility at SoundBite Communications from 2008 until its acquisition by Genesys in 2013, serving as Senior Financial Reporting Analyst from 2008 to 2010, as Financial Reporting Supervisor from 2010 to 2011 and as Financial Reporting Manager from 2011 to 2013. Ms. Romano also served as a Senior Financial Reporting Analyst at Cognex Corporation, a publicly-traded manufacturer of machine vision systems, software and sensors, from 2004 through 2008. Ms. Romano began her career as an Auditor in the Boston office of PricewaterhouseCoopers. A licensed CPA in Massachusetts, she holds a Bachelor of Arts in Accounting from College of the Holy Cross and Masters of Accounting from Boston College.

Lisa Brandano

Ms. Lisa Brandano serves as Vice President - Clinical Operations of the Company. Brandano joined EyeGate in 2011, and has served as Associate Director and Director of Clinical Operations. Prior to joining EyeGate, she served as Assistant Managing Director of the Boston Office and Director of Clinical Trial Operations at CATO Research, an international contract research organization. During her 11 years with CATO, she was involved in the oversight and facilitation of global clinical operations. Previously, she held clinical research coordinator and laboratory science roles at Beth Israel Deaconess Medical Center in Boston. Ms. Brandano holds a BS in biology from Emmanuel College, and since 2003, she has been a certified clinical research associate (CRA) with the Association of Clinical Research Professionals (ACRP).

Michael Manzo

Mr. Michael P. Manzo is Vice President - Engineering of Eyegate Pharmaceuticals, Inc. Mr. Manzo has over 30 years of experience in product development and manufacturing in the medical device industry. Prior to working at EyeGate, Mr. Manzo held positions of President and Chief Operating Officer (2002 – 2006) at Jenline Industries, Ltd., which is now part of Helix Medical, LLC. He has been part of multiple start-up companies over the years, ranging in medical specialties from cardiology, radiology, urology and laproscopic surgery. Mr. Manzo holds a Masters in Business Administration Degree from Suffolk University and a Bachelor of Science Degree in engineering from University of Massachusetts, Lowell.

Carol Assang

Ms. Carol Assang serves as Director - Clinical Operations of the Company. Ms. Assang joined EyeGate in 2010, and has been responsible for all aspects of clinical study planning and the execution of multiple clinical development programs. Prior to joining EyeGate, Ms. Assang served as an Associate Project Director/Senior Clinical Associate at New England Research Institutes, where she was responsible for clinical development and operations of several programs. Previously, Ms. Assang served as Program Manager at Harvard Clinical Research Institute, Clinical Studies Coordinator at Tufts-New England Medical Center, Associate Medical Program Coordinator at Merck and a Consultant at Alliance Pharmaceuticals. She holds a Bachelor's degree in Chemistry and Mathematics from Wesleyan University and Master's Degree in Chemistry from Yale University.

Mike Garanzini

Mr. Mike Garanzini is Chief Commercial Officer of the Company. Mr. Garanzini has more than 25 years of marketing experience in the pharmaceutical industry. Prior to joining EyeGate, he was the Global Marketing Therapy Leader for the Glaucoma Portfolio at Santen, where he was responsible for providing strategic direction to advance glaucoma products, including the acquisition and integration of the InnFocus MicroShunt. Prior to assuming that role, Mr. Garanzini served as Santen's Head of Marketing, Europe where he played a key role in the integration of the Merck Ophthalmic products, establishing operations throughout Western Europe and ultimately led the total portfolio of glaucoma, dry eye and retinal disease products. Previously, Mr. Garanzini was the Senior Director of Global Marketing, Ophthalmology at Merck, where he was in charge of overseeing strategic planning, medical education, opinion leader relations and co-promotion alliances on a global basis while also having specific geographical responsibility for Europe. Earlier in his career at Merck, Mr. Garanzini held two non-ophthalmic product-specific roles, as U.S. Director of Marketing for Levitra and Asmanex in the Primary Care markets where he gained important DTC experience. Mr. Garanzini has also held sales and marketing positions in Pharmacia's ophthalmology division, where he was part of the team responsible for the launch and growth phase of Xalatan and time managing surgical products used in cataract and glaucoma surgery. Mr. Garanzini holds a B.S. in Engineering from Michigan State University.

Barbara Wirostko

Dr. Barbara Wirostko, M.D., is Chief Medical Officer of the Company. She was a co-founder of Jade, is a board certified ophthalmologist and a fellow of the American Academy of Ophthalmology. Since 2010, she has maintained an academic research and clinical practice with the University of Utah, Moran Eye Center, as a Clinical Adjunct Associate Professor in Ophthalmology and as an Adjunct Associate Professor of Bioengineering. She served as a Development Lead at Pfizer from 2006 to 2010, where she led a successful EU regulatory EMA filing for Xalatan in pediatric glaucoma and for which she and her team were recognized. Dr. Wirostko received her undergraduate degree at Cornell University, College of Arts & Sciences in microbiology and her medical degree at Columbia University, College of Physicians & Surgeons. She interned at Hackensack Medical Center in transitional medicine and completed her residency in ophthalmology at Columbia Presbyterian Medical Center. Dr. Wirostko was awarded a fellowship at The New York Hospital Cornell Medical Center in glaucoma.

Thomas Balland

Mr. Thomas Balland was Independent Director of Eyegate Pharmaceuticals, Inc. He is a Managing Director at IPSA, a venture capital firm, where he has been since 2002. He has over 15 years of venture capital investment experience. In addition to the Company, Mr. Balland has invested in and serves on the boards of several biotech and medtech companies including CMC Biologics and SpineGuard. He was also on the boards of several companies that were acquired by larger entities in the life sciences industry, including Technolas Perfect Vision GmbH. Prior to joining IPSA in 2002, Mr. Balland held various positions with firms such as Mars, Inc. and Up&Up. He has degrees in engineering and finance from INSA Lyon and ESCP-EAP, respectively. We believe Mr. Balland’s qualifications to sit on our board of directors include his executive leadership experience and his business development, strategic planning and mergers and acquisitions experience with biotech and medtech companies.

Morton Goldberg

Dr. Morton F. Goldberg is an Independent Director of Eyegate Pharmaceuticals Inc. Since 2003 he has served as the Joseph E. Green Professor of Ophthalmology at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, to which position he was appointed to in 2003. From 1989 to 2003 he served as the Director and William Holland Wilmer Professor of Ophthalmology at the Wilmer Eye Institute. Prior to this, he was a Professor and Chairman of the Department of Ophthalmology at the University of Illinois College of medicine in Chicago for nearly 20 years. Dr. Goldberg trained at Johns Hopkins as a resident and chief resident, and holds a joint appointment at the Johns Hopkins Applied Physics Laboratory. He is also a past President of the Association for Research in Vision and Ophthalmology, the Macula Society, and the Association of University Professors of Ophthalmology. Dr. Goldberg received his undergraduate degree with honors from Harvard College and his MD with honors from Harvard Medical School.

Thomas Hancock

Mr. Thomas E. Hancock is an Independent Director of Eyegate Pharmaceuticals Inc. He has over fifteen years of experience in the biopharmaceutical industry and equity capital markets. Since September, 2004, he has been the a Principal of Nexus Medical Partners, where he has been responsible for several investments, including A&G Pharmaceuticals Inc., Magellan Biosciences, Inc., and Panacos Pharmaceuticals, Inc. and a principal of Nexus Investment Company, a FINRA member. Prior to joining Nexus Medical Partners, Thomas was a Senior Equity Analyst and Managing Director at US Bancorp Piper Jaffray, covering both the biopharmaceutical and drug discovery tools markets. He has also held numerous positions at Genentech, Inc. and COR Therapeutics, Inc. Mr. Hancock has a BS in Molecular Biology and an MBA from UC Berkeley. We believe Mr. Hancock’s qualifications to sit on our board of directors include his many years of biotech, investment banking and venture capital experience.

Bernard Malfroy-Camine

Dr. Bernard Malfroy-Camine is an Independent Director of Eyegate Pharmaceuticals Inc. He is a scientist-turned-entrepreneur with nearly 30 years of experience in biotechnology and drug discovery. Since May 2013, he has been President and CEO of ViThera Pharmaceuticals, Inc. He has also served as Director, Business Development US Operations at Voisin Consulting, Inc. (also known as Voisin Consulting Life Sciences) since September 2012. Since October 2008, Dr. Malfroy-Camine has also been Founder, President and CEO of MindSet Rx, Inc., a virtual company which is a continuation of Eukarion, Inc., a biotech company he had founded in 1991, and of which he was President and CEO. Dr. Malfroy-Camine has over 80 scientific publications and holds approximately 20 patents. He has a Master’s degree in Mathematics and Physics from Ecole Polytechnique (Paris) and a Ph.D. in Neurobiology from University Paris VI. We believe Dr. Malfroy-Camine’s qualifications to sit on our board of directors include his executive leadership experience and his extensive experience in entrepreneurship, drug discovery and drug development.

Praveen Tyle

Dr. Praveen Tyle, Ph.D. is an Independent Director of Eyegate Pharmaceuticals Inc. Dr. Tyle has served as Executive Vice President of Research and Development of Lexicon Pharmaceuticals. Dr. Tyle was previously a member of the executive management team at Osmotica Pharmaceutical Corp., serving as President and Chief Executive Officer from January 2013 through April 2016 and as Executive Vice President and Chief Scientific Officer from August 2012 to December 2012. He is also a member of the board of Orient EuroPharma Co., Ltd. of Taiwan. Dr. Tyle has nearly 30 years of experience in the pharmaceutical industry with the majority of his tenure in senior executive leadership positions in areas of research and development, manufacturing, quality, business development and operations. Prior to joining Osmotica Pharmaceutical Corp., Dr. Tyle served as Executive Vice President (from January 2012 to August 2012) and Chief Scientific Officer (from October 2011 to August 2012) for the United States Pharmacopeia, or USP. Prior to joining USP, Dr. Tyle from 2008 to 2011, served as the Senior Vice President and Global Head of Business Development and Licensing at Novartis Consumer Health from March 2009 to September 2011. At Novartis Consumer Health, Dr. Tyle also served as Senior Vice President & Global Head of Research and Development from March 2009 to February 2010. Dr. Tyle holds a doctorate in pharmaceutics and pharmaceutical chemistry from the Ohio State University and a BS in Pharmacy (honors) from the Institute of Technology, Banaras Hindu University in India.

Basic Compensation